

Medical Research Council Adult Acute Lymphoblastic Leukaemia Trial UKALL XA

Submission date 19/08/2002	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 19/08/2002	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
Last Edited 07/06/2012	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr - -

Contact details
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

Protocol serial number
MRC UKALL XA

Study information

Scientific Title

Study objectives
Not provided at time of registration.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration.

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Not Specified

Health condition(s) or problem(s) studied

Leukaemia (acute)

Interventions

All patients receive induction, central nervous system (CNS) prophylaxis and maintenance.

Patients are randomised to one of four treatment arms:

1. Arm A: Early intensification therapy to be given immediately after induction and before CNS prophylaxis.
2. Arm B: Late intensification therapy to be given following cranial radiotherapy at week 20 of maintenance.
3. Arm C: Intensification therapy to be given both immediately after induction and following cranial radiotherapy at week 20 of maintenance.
4. Arm D: No intensification therapy.

INDUCTION: Chemotherapy with vincristine, prednisolone, asparaginase, daunorubicin and intrathecal methotrexate.

INTENSIFICATION: Intensification therapy with vincristine, prednisolone, daunorubicin, thioguanine, etoposide, cytosine arabinoside and intrathecal methotrexate.

CNS PROPHYLAXIS: Cranial radiotherapy, intrathecal methotrexate plus mercaptopurine.

MAINTENANCE: Maintenance therapy consisting of daily mercaptopurine, weekly methotrexate, monthly vincristine plus prednisolone. Treatment to be given for total of two years following complete remission.

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

Not provided at time of registration.

Key secondary outcome(s)

Not provided at time of registration.

Completion date

31/12/1992

Eligibility**Key inclusion criteria**

1. Newly diagnosed ALL
2. Aged >25 years

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

Not Specified

Key exclusion criteria

Not provided at time of registration.

Date of first enrolment

01/01/1985

Date of final enrolment

31/12/1992

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre

UKCCCR Register Co-ordinator

London

United Kingdom

NW1 2DA

Sponsor information

Organisation

Medical Research Council (MRC) (UK)

Funder(s)

Funder type

Research council

Funder Name

Medical Research Council (MRC) (UK)

Alternative Name(s)

Medical Research Council (United Kingdom), UK Medical Research Council, Medical Research Committee and Advisory Council, MRC

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/10/1997		Yes	No